Appendix 4D
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The report indicates a significant decrease in revenue and an increase in losses compared to the previous period, primarily due to reduced sales of its life sciences research device. The company reported no dividends paid or declared during the current financial period, and its net assets increased significantly due to a recent capital raise. The financial position shows a strong working capital surplus, with cash reserves bolstered by the capital raised for clinical studies and regulatory submissions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/appendix-4d-56
Optiscan Imaging Limited on 6ix
Earlier from Optiscan Imaging
- Quarterly Activities/Appendix 4C Cash Flow Report
- Optiscan Initiates Head & Neck Cancer Imaging Study
- Optiscan Partners with ACL to Advance Digital Pathology
- Appendix 4E - Preliminary Final Report
- Entitlement Issue Prospectus
Later from Optiscan Imaging
- Optiscan Submits InSpecta FDA Dossier
- Optiscan Receives $1.69m R&D Tax Refund
- Second Anniversary of Optiscan and Mayo Clinic Agreement
- Halfway Mark Reached in Optiscan Breast Cancer Study
- Optiscan Launches InSpecta Device for Veterinary Medicine
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging